Duchenne muscular dystrophy (DMD) is a severe genetic disorder characterized by progressive muscle degeneration, primarily affecting young boys. The market for DMD therapeutics has made significant strides in recent years, particularly with the advent of exon-skipping therapies. However, the quest to improve patient outcomes has driven researchers and pharmaceutical companies to explore...
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian